XML 54 R33.htm IDEA: XBRL DOCUMENT v3.23.1
SEGMENT INFORMATION (Tables)
3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Schedule of Information about Reportable Segments and Reconciliation of Segment Net Sales and Pre-Tax Income
The table below presents information about Edwards Lifesciences' reportable segments (in millions):
 Three Months Ended
March 31,
 20232022
Segment Net Sales  
United States$849.1 $749.5 
Europe335.4 300.1 
Japan104.3 140.9 
Rest of World165.6 142.3 
Total segment net sales$1,454.4 $1,332.8 
Segment Operating Income  
United States$563.4 $511.5 
Europe181.7 166.6 
Japan63.4 99.5 
Rest of World70.5 59.7 
Total segment operating income$879.0 $837.3 
The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions):
 Three Months Ended
March 31,
 20232022
Net Sales Reconciliation  
Segment net sales$1,454.4 $1,332.8 
Foreign currency5.2 8.4 
Consolidated net sales$1,459.6 $1,341.2 
Pre-tax Income Reconciliation  
Segment operating income$879.0 $837.3 
Unallocated amounts:  
Corporate items(468.9)(419.4)
Intellectual property agreement and litigation expenses, net(43.5)(7.1)
Change in fair value of contingent consideration liabilities, net(0.7)2.9 
Foreign currency22.5 25.1 
Consolidated operating income388.4 438.8 
Non-operating income (expense)10.2 (2.7)
Consolidated pre-tax income$398.6 $436.1 
Schedule of Enterprise-Wide Information
The following enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements.
 Three Months Ended
March 31,
 20232022
Net Sales by Geographic Area  
United States$849.1 $749.5 
Europe331.1 311.1 
Japan114.1 135.5 
Rest of World165.3 145.1 
$1,459.6 $1,341.2 
Net Sales by Major Product Area  
Transcatheter Aortic Valve Replacement$947.9 $881.3 
Transcatheter Mitral and Tricuspid Therapies41.6 27.0 
Surgical Structural Heart248.2 220.8 
Critical Care221.9 212.1 
$1,459.6 $1,341.2